Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPT-302 plus ranibizumab versus ranibizumab alone in neovascular age-related macular degeneration
2020-004736-24Phase 3Active
- Sponsor
- Opthea Limited
- Start
- May 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sozinibercept in exudative macular degeneration (2 arms), sponsored by Opthea Limited. Primary endpoint: Mean change in ETDRS best-corrected visual acuity letters from baseline to Week 52. Started May 2021; status: active.
02
Drugs
sozinibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2020-004736-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004736-24.